| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 31
| Issue : 3 | Page : 91-98 |
|
|
Perspectives of medical treatment for overactive bladder
Chu-Tung Lin1, Bing-Juin Chiang2, Chun-Hou Liao2
1 Department of Surgery, Division of Urology, Cardinal Tien Hospital, New Taipei, Taiwan
2 Department of Surgery, Division of Urology, Cardinal Tien Hospital; School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
Correspondence Address:
Chun-Hou Liao
School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/UROS.UROS_16_20
|
|
|
Overactive bladder (OAB) syndrome is a clinical symptom diagnosis. Treatment strategies are aimed at relieving symptoms. Because antimuscarinic drugs are applied for OAB, several targets of treatment about OAB had been found and newer treatments were also discovered. Besides, further studies about the potential advantages of combination therapy are proved to have increased efficacy and acceptable tolerability. Our study aims to update clinicians managing an OAB with an overview of the existing and newer medical therapies for OAB, including pharmacology, efficacy, side effects, and impact on the patient's quality of life. We review the most frequently used pharmacological therapies and new agents aimed at treating OAB. PubMed and Medline were explored for randomized controlled drug trials in adults with OAB, meta-analyses of medical therapy for OAB, and individual drug names, including the keywords efficacy, tolerability, quality of life, and compliance. In conclusion, newer antimuscarinic drugs focus on more selective muscarinic receptors with less side effects. Some β3-adrenoceptor (β-AR) agonists had also been approved in Japan, and Phase III study is ongoing in the USA. In addition to antimuscarinic drugs and β-AR agonists, several newer treatments, such as intravesical botulinum toxin injection and phosphodiesterase-5 inhibitors, were proved to improve OAB symptoms. The new targets of treatment should be the focus of future studies.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
